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Abstract: Viral infections, such as those caused by Herpes Simplex Virus-1 (HSV-1) and SARS-CoV-2,
affect millions of people each year. However, there are few antiviral drugs that can effectively
treat these infections. The standard approach in the development of antiviral drugs involves the
identification of a unique viral target, followed by the design of an agent that addresses that target.
Antimicrobial peptides (AMPs) represent a novel source of potential antiviral drugs. AMPs have
been shown to inactivate numerous different enveloped viruses through the disruption of their
viral envelopes. However, the clinical development of AMPs as antimicrobial therapeutics has been
hampered by a number of factors, especially their enzymatically labile structure as peptides. We
have examined the antiviral potential of peptoid mimics of AMPs (sequence-specific N-substituted
glycine oligomers). These peptoids have the distinct advantage of being insensitive to proteases, and
also exhibit increased bioavailability and stability. Our results demonstrate that several peptoids
exhibit potent in vitro antiviral activity against both HSV-1 and SARS-CoV-2 when incubated prior
to infection. In other words, they have a direct effect on the viral structure, which appears to render
the viral particles non-infective. Visualization by cryo-EM shows viral envelope disruption similar
to what has been observed with AMP activity against other viruses. Furthermore, we observed
no cytotoxicity against primary cultures of oral epithelial cells. These results suggest a common
or biomimetic mechanism, possibly due to the differences between the phospholipid head group
makeup of viral envelopes and host cell membranes, thus underscoring the potential of this class of
molecules as safe and effective broad-spectrum antiviral agents. We discuss how and why differing
molecular features between 10 peptoid candidates may affect both antiviral activity and selectivity.
Keywords: antivirals; peptoids; LL-37; air-liquid interface; cytotoxicity; membrane disruption;
COVID-19; HSV-1; SARS-CoV-2
1. Introduction
Herpes simplex virus type-1 (HSV-1) infections cause recurrent oral lesions in the de-
veloped world, and are also the primary cause of infectious blindness and genital infections
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in developed countries. HSV-1 infections also can be life-threatening in immunocompro-
mised individuals [1]. Furthermore, there is recent evidence that HSV-1 infections are
associated with the pathogenesis of Alzheimer’s disease [2]. The HSV-1 virus is transmitted
readily through oral secretions. It is estimated that 40–80% of the population is infected
with this agent, depending on age and socioeconomic status [3]. The primary class of
antiviral therapeutics for this pathogen are nucleoside analogues, such as acyclovir or its
pro-drug valacyclovir. While acyclovir treatment can reduce the symptoms and shorten the
duration of the lesions, it is only effective when given orally, and only reduces the frequency
of lesions by approximately 50% [4]. In addition, there is evidence of the development
of resistance to this class of antivirals, especially in immunocompromised individuals [5].
Thus, the development of new, effective antiviral agents, which can be used topically to
inactivate the virus, is a necessity.
The innate immune system is one of the primary mechanisms for recognizing and
eliminating pathogens from mucosal surfaces (reviewed in [6]). Antimicrobial peptides
(AMPs) represent an important component of this defense. AMPs are ubiquitous, in-
tegral components of innate immunity across phyla, and are promising leads for new
antiviral therapies [7] through a number of possible mechanisms. For example, we have
recently shown that the human cathelicidin AMP, LL-37, is virucidal for Kaposi’s Sarcoma-
associated Herpes Virus (KSHV), through a mechanism by which the cationic peptide
disrupts the viral envelope [8].
While many AMPs are potent and selective antibiotics, the typically poor bioavail-
ability of peptides limits their clinical use primarily to topical applications. As a result,
only a few AMPs are currently being targeted for systemic delivery [9,10]. Additionally,
despite advances in chemical synthesis, manufacturing costs of peptides are still higher in
comparison to small-molecule drugs [9,11]. Moreover, while it is possible to improve the
protease resistance of AMPs (while maintaining their activity) by designing them with all
D-amino acids, this approach significantly increases the cost of peptide synthesis [12,13].
The challenges of using AMPs as therapeutics has spurred the development of non-
natural peptidomimetics such as ‘peptoids’, which are sequence-specific N-substituted
glycine oligomers [14,15]. Peptoids are isomerically related to peptides in that their side
chains are appended to the backbone amide nitrogens rather than to backbone α-carbons.
As a result, peptoids are not proteolyzed by proteases that may be present in the host
environment. Furthermore, compared to their peptide counterparts, peptoids have im-
proved biostability and bioavailability, and reduced immunogenicity [16,17]. Peptoid
monomer sequences can be designed to form highly stable, amphipathic helices that do
not denature. In particular, unlike the helices of peptides which are stabilized by labile
hydrogen bonds, the helices of peptoids are stabilized mostly by steric, van der Waal’s and
other electronic forces [18–20].
Another major advantage of peptoids is that they can be readily synthesized on a
peptide synthesizer (typically using a commercially available Rink™ Amide resin), and can
be cleaved by trifluoroacetic acid and purified by HPLC. The stepwise “sub-monomer” pro-
cedure of adding peptoid repeat units is simpler and less costly than that the corresponding
synthesis of peptides [21]. This procedure can be programmed into an automated peptide
synthesizer, allowing easy introduction of a variety of side chains that can mimic the
structures of most of the 20 natural amino acids, as well as allow the easy introduction of a
virtually endles variety of novel side chains [22]. Antimicrobial peptoids have been shown
to be analogous to AMPs in terms of their efficacy and structure-activity relationships,
thus, suggesting that the two classes of antimicrobial compounds operate via analogous
mechanisms [14,23–25]. Furthermore, they are generally non-immunogenic, requiring
the attachment of a carrier protein to produce an antibody response [26]. Thus, antimi-
crobial peptoids have significant potential to be developed as a novel class of biostable,
peptidomimetic drugs with advantageous properties.
Based on the results demonstrating the inactivation of enveloped viruses with AMPs
through a membrane-disruption mechanism, we hypothesized that antimicrobial pep-
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toids would inactivate an enveloped virus such as HSV-1. In addition, since the recently
emerged virus, SARS-CoV-2 (the etiologic agent of COVID-19), is similarly enveloped,
we further hypothesized that these peptoids would exhibit similar activity against this
devastating virus.
Peptoid 1 [H-(NLys-Nspe-Nspe)4-NH2], designated here as MXB-1, is a 12-mer with
the trimer sequence motif NLys-Nspe-Nspe repeated four times (structures of the monomers
are shown in Figure 1A). It is a helical peptoid with broad-spectrum activity against a vari-
ety of pathogens [25,27], including viruses as shown here; it is also active against fungi [28]
and bacterial biofilms [29]. Despite these promising features, early in vitro studies raised
some concerns about the apparent cytotoxicity of Peptoid 1 (notably, however, Peptoid 1
was found to be reasonably well tolerated when delivered intraperitoneally to treat a bacte-
rial infection [25]). We undertook the development of novel analogs of Peptoid 1 that could
exhibit reduced cytotoxicity, without compromising the broad-spectrum antimicrobial
characteristics of the compound.





Figure 1. Structure of peptoids. (A) Structures of peptoid submonomers used in this library of new 
compounds. (B) Chemical structures of the ten different peptoids used in this study. 
Molchanova et al. found that short (6 mer), Figure 1 brominated analogues of Peptoid 
1 not only exhibited significantly reduced cytotoxicity, but relative to non-brominated 
compounds, displayed up to a 32-fold increase in activity against S. aureus and a 16- to 64-
fold increase in activity against E. coli and P. aeruginosa. They ascribed these results to the 
relatively increased hydrophobicity and self-assembly properties of the compounds. In 
particular, they obtained small angle X-ray scattering (SAXS) data which demonstrated 
how the self-assembled structures are dependent on the size of the halogen, the degree of 
halogen substitution and the length of the peptoid, and they correlated these features to 
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After studying more than 120 peptoid sequence variants, a number of unique pep-
toids were identified that exhibited potent, broad-spectrum antibacterial in vitro activity.
Like the human antibacterial peptide LL-37 and MXB-1 itself, these peptoids induce a
rapid rigidification of bacterial cytoplasm as their biomimetic mechanism of action [30], a
remarkable biophysical phenomenon that turns early beliefs about AMP mechanisms of
action on their head, and which we are currently exploring more deeply.
This effort led to the development of MXB-5 [H-Ntridec-NLys-Nspe-Nspe-NLys-NH2;
see Figure 1 for structure), a peptoid with a 13-carbon N-terminal alkyl modification, that
shares some structural similarities with MXB-1 [31]. MXB-5 was found to be highly active
against several pathogens as well as against Pseudomonas aeruginosa biofilms [29], and
was also found to be significantly less cytotoxic to mammalian cells than MXB-1 [32]. In
one in vivo experiment which has been presented orally online [33], mice were infected
intratracheally with bioluminescent Pseudomonas aeruginosa, and were then treated with
MXB-5. The peptoid provided a significant reduction in bacterial loads compared to
untreated animals, and was also well tolerated in the lungs of the mice. However, MXB-5
was not active against all of the same pathogens that MXB-1 is active against [2].
Given the partial success of MXB-1 and MXB-5, a further library of compounds was
developed by hybridizing the key features of these compounds. The activity and potency
of these cationic, amphipathic peptoids was found to be affected by their self-assembly
into stable, ellipsoidal micelles or other structures (unpublished results; and [34]).
The other contribution to this library came in the form of halogenated peptoids,
which were first developed and explored by Molchanova et al. [34]. They synthesized a
library of 36 halogenated analogs of MXB-1. These peptoids contained fluorine, chlorine,
bromine and iodine atoms, and varied by length and by the level of halogen substitution
in position 4 (the para position) of the phenyl rings. Compared to an inactive peptoid
hexamer comprising one-half of Peptoid 1/MXB-1 (NLysNspeNspeNLysNspeNspe), some
of these compounds exhibited improved antimicrobial activity.
Molchanova et al. found that short (6 mer), Figure 1 brominated analogues of Peptoid
1 not only exhibited significantly reduced cytotoxicity, but relative to non-brominated
compounds, displayed up to a 32-fold increase in activity against S. aureus and a 16- to
64-fold increase in activity against E. coli and P. aeruginosa. They ascribed these results to
the relatively increased hydrophobicity and self-assembly properties of the compounds. In
particular, they obtained small angle X-ray scattering (SAXS) data which demonstrated
how the self-assembled structures are dependent on the size of the halogen, the degree
of halogen substitution and the length of the peptoid, and they correlated these features
to the activity of the resulting peptoid. Thus, the creation of the peptoid library tested in
this study hybridizes the molecular features of three different peptoid motifs: (1) inclusion
of the NLysNspeNspe trimer sequence motif; (2) N-terminal alkylation with either a C10
or C13 chain; (3) inclusion of para-brominated (at position 4 in the phenyl ring) Nspe
monomers. Within a library comprising these attributes, we identified numerous active
antiviral peptoids.
2. Results
We tested the 10 peptoids shown in Figure 1B (as well as the natural human host
defense peptide LL-37) for activity against HSV-1. This was accomplished by incubating
the virus with the peptoid at 20 µg/mL for 2 h at 37 ◦C, prior to using the incubated virus
to infect cultures of OKF6/TERT-1 cells. An initial screening of the peptoids (Figure 2A)
showed wide variability in activity, with MXB-10 exhibiting no inhibitory activity. In a
separate study, MXB-6 also showed no activity (data not shown). We chose five peptoids
to study further. The results in Figure 2B show a dose-dependence with strong activity at
20 µg/mL for MXB-4, MXB-5 and MXB-9 (corresponding to 15 µM, 21.2 µM and 14.5 µM,
respectively). MXB-4 and MXB-5 showed a time-dependent inactivation of HSV-1, with
activity seen as early as 30 min. MXB-9 exhibited the most potent activity, with complete
inhibition of the virus after as little as 30 min (Figure 2C). Since the virus strain expressed
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Green Fluorescent Protein (GFP), we could observe fluorescence in the cells at 24 h post-
infection, indicating viral replication. The control (medium) treated virus exhibited strong
fluorescence, while the cultures infected with the virus treated with MXB-5 showed very
weak fluorescence in a small number of fluorescent cells. We were required to increase the
exposure significantly in order to observe the minimal fluorescence in the peptoid-treated
cultures, which led to a bright background (Figure 2D).
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Figure 2. Activity of peptoids and of LL-37 against S -1. ( ) r i ,
with comparison to the antiviral activity of LL-37, which is known to be active against SV-1. The
virus was treated with peptoids at 20 µg/mL for 2 h at 37 ◦C, followed by infection of OKF6/TERT1
cells for 24 h. Total DNA was isolated and HSV-1 DNA was quantified by QPCR relative to β-actin.
(B) Activity of peptoids MXB-4, MXB-5 and MXB-9 at 5 µg/mL and 20 µg/mL for 2 h. (C) Time
course of MXB-4, MXB-5 and MXB-9 activity. (D) Fluorescence imaging of HSV-1 infection 24 h. after
treatment with either control (media) or MXB-5 (20 µg/mL for 2 h). Results shown are representative
of at least two independent experiments.
Our previous results demonstrated that LL-37 disrupted the membrane of Kaposi’s
Sarcoma Herpes Virus (KSHV) [8]. Thus, we hypothesized that these peptoids, which are
simplified structural mimics of natural antimicrobial peptides, would act through a similar
biophysical mechanism. To examine this, we treated HSV-1 with peptoids, followed by
electron microscope imaging of the peptoid-treated viral particles. Using negative staining
EM (Figure 3A) we observed disruption of the viral membrane in all treated samples,
compared with virus that was treated with PBS alone. Since negative staining procedures
could potentially cause modification of the virus owing to chemical treatment of the sample
by a heavy metal (tungsten) salt, we decided to verify the results by using cryo-EM without
chemical fixation or negative staining. Both techniques lead to the same conclusion.
Selected examples of cryo-EM images are shown in Figure 3B, with two different
representative images in each column. The images show clearly resolved viral envelope
in the control panels. In the treated samples, there are images showing both partially
disrupted envelopes, as well as numerous capsids without envelopes, suggesting a total
disruption of the membrane. Quantification of the images (Figure 3C) show that while a
small number (21%) of unenveloped capsids are observed in the untreated controls, we
see a large increase in both unenveloped capsids (bottom panels, MXB-5 and MXB-9) and
disrupted envelopes (top panels). These results are similar to what we observed with
treatment of KSHV with LL-37 [8].
Pharmaceuticals 2021, 14, 304 6 of 14
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(C) Quantification of relative amounts of whole virus, disrupted envelopes and naked capsids that
were observed in the cryo-EM images.
To determine whether the peptoids would exhibit similar activity against other en-
veloped viruses, we tested the inhibitory activity of MXB-4 and MXB-9 against SARS-CoV-2.
When incubated with virus for 1 h at 37 ◦C at increasing concentrations, we observed an-
tiviral activity with approximate IC50 values of 20 µg/mL and 7 µg/mL, respectively
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(Figure 4). Thus, these two peptoids are active at similar relative concentrations against
both viruses.
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To determine whether the peptoids acted through a similar membrane-dependent
mechanism as with HSV-1, we treated SARS-CoV-2 with the two active peptoids (MXB-4
and MXB-9) follow by visu lization by Cryo-EM. While SARS coronavir s s to do not
exhibit the well-formed h xagonal capsids observed in HSV-1 [35], we observed numerous
partially disrupted envelopes as well as what appear t be un nveloped nucleocapsids
(Figure 5). We did not observe these structures in the control sa ples, suggesting that
the peptoids are acting through a similar membrane-disruptive mechanism on both types
of virus.
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3. Discussion
Herpesvirus infections are common and easily tra smissible. However, due to the
mechanisms of inf ction and pathogenesis at play, it has be n difficult to esign any ef-
fective vaccines to pr vent herpesvirus infecti ns. Furthermore, other preventive and
palliative methods have been challenging to adapt to broad clinical use. Si ce AMPs such
as LL-37 exhibit potent activity against HSV-1 [36], their potential as antiviral preventive
or therapeutic agents is significant. However, direct introduction of these peptides has not
translated into effective treatments, due to high cost, molecular instability, and unknown
pharmacokinetics, among other problems [37,38]. Here, we have demonstrated the po-
tential use of a novel AMP mimetic structure which, based on its mechanism of action,
not only inactivates HSV-1, but can be used against other, potentially more dangerous
enveloped viral pathogens such as SARS-CoV-2.
Conventional development of antiviral therapeutics usually is based on designing
drugs that target enzymes or other targets specific to each virus. On rare occasions, drugs
such as Remdesivir, which was originally designed to treat Ebola virus infections by
targeting the RNA-dependent RNA polymerase of the virus, can have some efficacy in
COVID-19 [39]. However, in general, this means that new therapeutic agents must be
developed for each virus. The advantage of AMPs and antimicrobial peptoids is that they
often target membranes, regardless of microbial species. In many cases, AMPs have been
shown to disrupt the viral envelope, although other non-membrane dependent mechanisms
have also been observed [7]. Confirming the results of Gordon et al. [36], and in contrast
to the results shown by Roy et al. [40], we observe direct inactivation of HSV-1 by LL-37
outside of the cell. This inactivation is presumably due to the damage to the viral envelope
we observed by EM, which would prevent binding and infection. This is in contrast to
the small antiviral molecule, LJ001. This therapeutic intercalates into the viral envelope,
thus interfering in membrane fusion, without causing envelope disruption [41]. Thus, we
hypothesized that antimicrobial peptoids would similarly inactivate enveloped viruses.
Our results clearly show inactivation of HSV-1, with widely variable activity among the 10
different peptoids we studied, which is quite remarkable given many similarities in their
structures. Some were completely inactive, e.g., Peptoid MXB-6.
Comparing the structures of the ten peptoids on our new library with regard to
antiviral activity, halogenation seems to be beneficial as every active compound (except
MXB-5) includes at least two Nspe(p-Br) submonomers. Interestingly, shortening of the
peptoid oligomers seems to be an issue as well. MXB-5 is the only derivative that is not
characterized by at least two helix turns, but shows strong activity despite its lack of
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halogen substituents. HSV-1 inhibition appears strongly structure-dependent, as slight
changes result in structure give rise to significantly different activities. For example, while
MXB-9 exhibits potent antiviral activity, its structural analog MXB-10 has no effects on
viral propagation. This difference in activity potentially can be explained by differences
in net molecular hydrophobicity upon halogen substitution as previously reported by
Molchanova et al. [34]. In this study they found an increasing antimicrobial activity
correlating with increasing hydrophobicity, until a threshold was reached where the activity
dropped. Beyond the hydrophobicity, recent Small Angle X-ray Scattering data we have
acquired for these peptoids in aqueous media have revealed large differences in the self-
assembled structures of the peptoids in aqueous PBS buffer. While MXB-9 and MXB-5
both seem to self-assemble into stable core-shell ellipsoidal micellar structures, MXB-10
forms long worm-like cylinders in solution (unpublished data, manuscript in preparation)
which may provide an explanation for differences in activity for these peptoids. Further
studies are needed to make definitive conclusions about these effects. We believe that a
certain type and degree and stability of peptoid self-assemblies in aqueous media can be
an important determinant of both activity, and selectivity. If assemblies remain intact near
zwitterionic mammalian cells, but disassemble near anionic pathogenic membranes, they
can be selective towards affecting pathogens while causing little to no harm to the host.
Lack of cytotoxicity for the host cell is important for any therapeutic. Since HSV-1
generally affects oral epithelial tissues, we tested the active peptoids on well-differentiated
3D cultures of oral epithelium. The drugs were applied to the apical surface, and showed no
cytotoxic effects after a 3-h exposure. This is in line with results routinely obtained with AMPs
such as LL-37, which only exhibits cytotoxic effects on host cells at high concentrations [40].
This raises a very interesting question regarding the mechanism. Our results strongly
suggest that, like known AMP activity against bacteria and fungi, the peptoids target and
disrupt pathogenic membranes. For bacteria and fungi, the difference between the micro-
bial membrane and the host cell membrane is striking. Microbial phospholipid bilayers
have predominantly anionic headgroups on the outer leaflet, in contrast to mammalian
cells where the anionic headgroups are mostly on the inner leaflet. This allows for increased
binding of cationic peptides, which leads to the formation of pores or other membrane dis-
rupting events (reviewed in [42]). However, viral envelopes are obtained from the host cell,
thus suggesting that peptoids or peptides would have a similar propensity for binding to
viral membranes as they do to the host cell membrane. Since neither peptoids nor peptides
exhibit cytotoxicity at the same concentrations at which they exhibit viral inhibition, this
implies either that the makeup of the outer leaflet of the viral envelope differs from that
of the host cell membrane, or that some other structural features of the viral envelope are
encouraging binding. It is known that the envelopes of many enveloped viruses contain
phospholipid head groups that differ from those in the host cell membrane, including
that of HSV-1 [43]. Indeed, they often contain increased levels of phosphatidylserine, a
negatively charged headgroup that is usually found in the inner leaflet of the plasma
membrane [44]. This switching allows the virus to appear more like an apoptotic cell in
order to increase uptake by host cells. Recently, a cationic AMP was shown to exhibit
increased binding to a number of enveloped viruses through binding to the PS on the
envelopes of these viruses [45].
Other possible features of the viral envelope that could enhance peptoid binding could
include the curvature of membrane (which is much stronger in the small viral particle),
or an abundance of negatively charged amino acids in the glycoproteins on the surface
of the envelope. Due to its much smaller radius, the outer leaflet of the viral particle
has an 11% greater surface area than the inner leaflet (as opposed to cells, in which this
difference in surface area is only 0.1%) [46]. This feature may enhance interaction with
the peptoid. Furthermore, a recent study showed that LL-37 binds to the spike protein of
SARS-CoV-2 [47], This suggests that the initial interaction of the peptoid with this virus is
through binding to the spike protein, rather than to the membrane itself. Further research is
necessary to understand completely how AMPs and antimicrobial peptoids can distinguish
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between viral envelopes and host cell membranes. However, regardless of the specific
molecular mechanism, our results suggest that peptoids of the type described herein could
be developed as broad-spectrum antivirals that could target numerous enveloped viruses,
including those which are highly pathogenic.
4. Materials and Methods
4.1. Viral Strains and Antiviral Assays
HSV-1-GFP was propagated in Vero E6 cells, plaque purified and titered as de-
scribed [48]. Stocks were aliquoted and maintained at 108 pfu/mL in −80 ◦C. Virus
was diluted to 105 pfu/mL, and incubated with peptoids at 37 ◦C. Samples were removed
and added to cultured OKF6/TERT-1 cells at an MOI of 0.1:1 in triplicate, and incubated
at 37 ◦C for 24 h. Cells were lysed and total DNA was isolated using a DNA isolation kit
(Qiagen). HSV-1 genomic DNA was quantified by QPCR relative to genomic -actin DNA.
Results were presented as fold change compared to control.
SARS-CoV-2 (strain USA-WA1/2020 isolate; BEI resource cat# NR-52281) was obtained
from BEI resources and amplified in Vero E6 cells. Amplified stock virus was stored at
−80 ◦C until used. For antiviral activity test, virus was diluted in cell culture media to
2000 pfu/mL and mixed with peptoids 1:1 in volume. The mixture was further incubated
at 37 ◦C for one hour and 250 µL of mixture was added to Vero E6 cells grown in 12-well
plates. After one hour of incubation, cells were washed once with PBS and overlayed with
Avicel overlay media (1% Avicel in DMEM with 10% FBS). Three days later, the overlay
media were removed and cells were stained with crystal violet solution (1% crystal violet,
2% paraformaldehyde, 25% Ethanol) for 4 h. Viral plaques were counted and compared to
the mock treated samples. Experiments were performed with three replicates per treatment.
SARS-CoV-2 (strain USA-WA1/2020 isolate) was provided by the World Reference
Center for Emerging Viruses and Arboviruses (WRCEVA). Vero76 cells were infected with
an MOI of 3 and the infection allowed to progress for 48 h. Supernatants from infected
cells were collected and a primary centrifugation of 10,000× g was performed for 30 min.
Supernatants from this centrifugation were carefully removed to prevent the disruption of
the pelleted debris. Supernatants were then laid upon a 10 mL cushion of 20% sucrose and
centrifuged for 3 h at 100,000× g. Supernatants and sucrose were removed following virus
pelleting and the virus pellet resuspended in PBS for immediate cryo-EM processing.
Vero E6 cells (ATCC CRL-1586) were obtained from ATCC and cultured in DMEM
(HyClone. Cat. SH30243.FS) with 10% FBS. The cells were cultured in a 37 ◦C incubator
with 5% CO2 and passaged every 7 days.
4.2. Cytotoxicity
Normal human bronchial epithelial cells, obtained from MatTek (EpiAirway) were
grown at an air-liquid interface at 37 ◦C. Serial dilutions of peptoid were performed in
triplicate using 400 µM peptoid stocks resulting in final concentrations between 200 µM and
6.25 µM. Peptoids were applied to the apical surface of cultures in 100 µL for three hours.
Cell viability was quantified using the CyQUANT MTT Cell Viability Assay (ThermoFisher,
Waltham, MA, USA), following the manufacturer’s instructions Absorbance was read at
540 nm and percent survival was calculated relative to untreated cultures. Ethanol was
used as a positive control for cytotoxicity.
4.3. RNA/DNA Isolation
Cells were harvested and homogenized using Qiagen QIAshredder protocol. The
obtained lysate was then used to extract RNA and DNA using the Qiagen RNeasy Plus
Micro kit. Once RNA was extracted using the manufacturer protocol, DNA was extracted
as described [49]. Using the same RNeasy spin columns 50 µL of 8.0 mM NaOH was added
directly to membrane. The tubes were then incubated for 10 min at 55 ◦C. DNA was eluted
by centrifugation for 3 min at 5000× g.
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4.4. Quantitative Polymerase Chain Reaction
qPCR was performed on a BIO RAD myCycler using SsoAdvanced Universal SYBR
green supermix (Bio-RAD #1725274). Purified HSV1 DNA (1.5 µL) was used as the template
for each reaction mixture. Relative HSV-1 DNA levels were quantified using HSV UL30
(F: AGAGGGACATCCAGGACTTTGT; R: CAGGCGCTTGTTGGTGTAC), normalized to
β-Actin (F: GGA TCA GCA AGC AGG AGT ATG; R: AGA AAG GGT GTA ACG CCA
CTA A) in each sample, and the change in expression was determined using the 2−∆∆Ct
method compared to control treated samples.
4.5. General Synthesis of Peptoids
Peptoids were synthesized manually in accordance with the submonomer method [21].
All reaction steps were performed in fritted 10 mL syringes under smooth mixing on a
VWR® Tube Rocker at 21 ◦C. Rink amide MBHA resin (Protein Technologies Inc., Tucson,
AZ, USA, 0.64 mmol/g) was used as a solid support. Acetylation steps were carried out
for 30 min, substitution for 1 h. Substitution with alkylamines was performed overnight.
Acetylation using bromoacetic acid and substitution by various amines were alternated
until the desired chain length was achieved. The single oligomers were cleaved and de-
protected simultaneously using a cocktail of trifluoroacetic acid/triisopropylsilane/water
(95:2.5:2.5 (v/v)) for 30 min. After purification, exchange of the counterion was carried out
using a 10 mM solution of aqueous HCl. Lyophilization yielded the desired compound.
Purity was determined to exceed 95%.
4.6. Peptoid Purification
Starting materials and solvents were purchased from commercial suppliers (Acros
Organics, Alfa Aesar, Chem-Impex Intl. Inc., CNH Technologies, Merck, OmniSolv, Protein
Technologies, Sigma-Aldrich, TCI, and VWR) and used without further purification. Water
was filtered through a 0.22-µm Millipore membrane filter.
Product formation and purity were determined by means of analytical UPLC/MS
using a Water Acquity UPLC system, equipped with an Acquity Diode Array UV detector
and a Waters SQD2 mass spectrometer As stationary phase, a Waters Acquity UPLC Peptide
BEH C18 Column (300 Å pore size, 1.7 µm particle size, 2.1 mm × 100 mm) with an Acquity
UPLC BEH C18 VanGuard pre-column (1.7 µm, 2.1 mm × 5 mm) was employed. For
alkylated derivatives, a Waters Acquity UPLC BEH300 C4 column (300 Å pore size, 1.7 µm
particle size, 2.1 mm × 100 mm) with an Acquity UPLC BEH300 C4 VanGuard pre-column
(1.7 µm, 2.1 mm × 5 mm) was used. Elution was performed using an aqueous acetonitrile
gradient with 0.1% (v/v) trifluoroacetic acid added (5–95% acetonitrile (v/v) over 6.80 min,
flow rate: 0.8 mL/min, column temperature: 60 ◦C). UPLC chromatograms are available
in the supporting information (see Supplementary Figure S1). The mass spectra were
collected in ESI+ mode.
Purification by means of preparative HPLC was carried out using a Waters Prep150LC
system, equipped with a Waters 2489 UV/Visable detector and a Waters Fraction Collector
III collector. As stationary phase, a Waters XBridge BEH300 Prep C18 column (5 µm
particle size, 19 mm × 100 mm) with a Waters XBridge Peptide BEH300 C18 guard column
(5 µm particle size, 19 mm × 10 mm) was employed. For alkylated derivatives, a Waters
Symmetry300 C4 column (5 µm particle size, 19 mm × 100 mm) with a Waters Symmetry300
C4 guard column (5 µm particle size, 19 mm × 10 mm) was used. Elution was performed
using an aqueous acetonitrile gradient with 0.1% (v/v) trifluoroacetic acid added (20–60%
acetonitrile (v/v) over 30 min at a flow rate of 17 mL/min).
4.7. Electron Microscopy
4.7.1. Negative Staining EM
HSV-1 (1 × 108 pfu/mL) was incubated with peptoids or control medium for 2 h.
at 37 ◦C. After incubation, the virus was fixed by addition of 2 volumes 4% glutaralde-
hyde/PBS, and fixed at 4 ◦C for 24 h. Virus was applied to grids (ultrathin carbon with
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lacey support film, Ted Pella, Inc.) for 1 min, followed by staining in 1% phosphotungstic
acid for 1 min. Excess liquid was blotted and grids were allowed to air dry. Images were
collected using a Thermo Scientific™ Talos™ F200X at 200 kV accelerating voltage with
50 µm objective aperture inserted to enhance contrast. Images were captured using a
4k × 4k CMOS camera (Thermo Scientific, Waltham, MA, USA, Ceta 16M™).
4.7.2. Cryo-EM
After incubation of HSV-1 virus with peptoids for 2 h. at 37 ◦C, samples were vitrified
using Leica EM-GP2® plunger (Leica Microsystems) as previously described [50] on carbon
holey film (R2 × 1 Quantifoil®; Micro Tools GmbH, Jena, Germany) grids. Briefly, suspen-
sions of virions were applied to the holey films, blotted with filter paper, and plunged into
liquid ethane.
SARS Co-V-2 was incubated with peptoids similar to the HSV-1 (two hours at 37 ◦C)
and vitrified also on R2 × 1 Quantifoil grids using a manual cryo-plunger [51] in a biosafety
cabinet. All experiments, including EM imaging were performed in a biosafety level 3
(BSL-3) containment because of the NIH/CDC classification of the virus.
The grids were imaged in a JEOL 2200FS electron microscope (JEOL, Tokyo, Japan).
The microscope was operated at 200 keV; we used 20 eV electron energy filter slit for
image acquisition. A Fischione Instruments 2550 cryo-transfer side-entry holder (E.A.
Fischione Instruments, Inc., Export, PA, USA) was used for data collection. The image were
acquired on DE-20 (Direct Electron, San Diego, CA, USA) camera, used in linear mode with
25 frames/s rate. Total electron dose/image was ~25 electrons/Å2. Image pixel size was
1.5 Å on the specimen scale.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/ph14040304/s1, Figure S1: LC/MS Traces for peptoids.
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